Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of the white paper Reforming Biopharmaceutical Pricing at Home and Abroad. The reportasserts that the United States’ healthcare bill – the largest in the world per capita by quite a margin – is due to inefficient regulation and foreign governments which demand universal healthcare and low prices for their citizens, leaving the US to foot the rest of the bill and allow manufacturers to see a return on their investments.
Pharmafocus March 2018 is available to read online now!
